Last reviewed · How we verify

NCT06151444

Intensive Versus Standard Treatment for Hypotension on Maternal Hemodynamics in Preeclamptic Patients

Status unknown NA Last updated 30 November 2023
What this trial tests

NA trial testing Alpha-Agonist in Adverse Effect in 160 participants. Status unknown.

Timeline
1 July 2024
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorGeneral Hospital of Ningxia Medical University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment160
Start date1 July 2024
Primary completion31 December 2024
Estimated completion31 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

General Hospital of Ningxia Medical University

Who can join

Adults 18 to 45, female only, with Adverse Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to investigate the impact of varying maternal blood pressure maintenance targets on maternal hemodynamics in preeclamptic patients following cesarean section.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Alpha-Agonist

Trials testing the same drug.

Other recruiting trials for Adverse Effect

Currently open trials in the same condition.

Other General Hospital of Ningxia Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06151444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing